Proof:
"Relapse & Antipsychotic Treatment in Schizophrenia Change Brain", by Dr. Nancy Andreasen, as published in The American Journal of Psychiatry, 2013:
http://bbrfoundation.org/brain-matters- ... ange-brain
http://ajp.psychiatryonline.org/article ... id=1676090
Conclusions
Extended periods of relapse may have a negative effect on brain integrity in schizophrenia, suggesting the importance of implementing proactive measures that may prevent relapse and improve treatment adherence. By examining the relative balance of effects, that is, relapse duration versus antipsychotic treatment intensity, this study sheds light on a troublesome dilemma that clinicians face. Relapse prevention is important, but it should be sustained using the lowest possible medication dosages that will control symptoms.
And also proof:
"Schizophrenia changes brain structure: A Review of Studies of Individuals with Schizophrenia Never Treated with Antipsychotic Medications", By E. Fuller Torrey, M.D. Stanley Medical Research Institute, 2002:
http://mentalillnesspolicy.org/medical/ ... renia.html
http://www.ncbi.nlm.nih.gov/pubmed/12409150
Summary
A review of 56 studies of individuals with schizophrenia who had never been treated with antipsychotic medications indicates significant abnormalities in brain structure and function. Neurological and neuropsychological measures show the most consistent and largest group differences between those affected and normal controls. Measures of structural differences and cerebral metabolic function are significant but less impressive. Electrophysiological differences also are found, but most such studies are older and have methodological problems. The brain abnormalities implicate a variety of interrelated brain regions, primarily the medial temporal, prefrontal, thalamic, and basal ganglia areas. It is concluded that schizophrenia is a brain disease in the same sense that Parkinson’s disease and multiple sclerosis are, and that the brain abnormalities in schizophrenia are inherent in the disease process and not medication-related. The challenge for the future is to use the new molecular techniques to study these brain areas and elevate our understanding of schizophrenia’s etiology to the next level.